Objectives

The main goal of the proposed project is to develop innovative semisolid formulations for skin-directed therapy of CTCL, in which the bioactive principle is confined within a biocompatible inorganic matrix, in order to attain maximum efficiency with minimum side effects when administered topically.

The objectives of the project are:

1. Development of modified drug delivery systems (MDDS) by immobilization of CTCL-specific anticancer drugs into biocompatible nanoporous matrices within 10 months from the start of the project.

2. Assessment of the role that the matrix nanostructure plays on the release behavior of selected model drugs: in-vitro release kinetics

3. Development of semisolid pharmaceutical product incorporating the MDDS suited for skin-directed therapy of CTCL

4. Evaluation of in-vitro dissolution of CTCL-specific active principles from the formulated semisolid pharmaceutical product

5.  In- vivo evaluation of chemoprevention potential and therapeutic efficacy of MDDS-based topical formulations

6.  Transfer of the research results into private sector: patent application and scale-up.